{
}
Roche shares rose 1.3% on Zurich's SMI index following an upgrade from UBS, which changed its recommendation from 'neutral' to 'buy' and increased the price target from CHF 300 to CHF 338. The firm highlighted sustainable growth driven by key products like Vabysmo and Ocrevus, with potential for $16 billion in additional sales from drugs in development for various conditions.
Siemens AG, a leading manufacturer of electronic and electrotechnical equipment, reports net sales across various sectors: medical equipment (30.2%), intelligent building solutions (28.8%), digital industrial equipment (25%), mobility solutions (15.4%), and financial activities (0.6%). Geographically, sales are distributed with 14.9% in Germany, 31.5% in Europe/CIS/Africa/Middle East, 26.4% in the U.S., 4.9% in the Americas, and 22.3% in Asia and Australia.
Pfizer's shares have shown mixed performance recently, with a slight decline to EUR 24.50 on February 13, 2025, following a positive trading day that saw a rise to EUR 25.22. The company reported a 7% increase in annual revenue to $63.6 billion for 2024, driven by strong sales of Covid-19 drugs and other key products, while maintaining a shareholder-friendly dividend policy. Analysts have adjusted their price targets, with ratings ranging from "Buy" to "Neutral," reflecting a cautious but optimistic outlook for 2025.
Celldex has been initiated with a Buy rating by UBS, indicating positive expectations for the company's performance in the market. This recommendation highlights the potential for growth and investment opportunities within Celldex.
UBS has upgraded AstraZeneca to a 'buy' rating, highlighting the company's "sector-leading" drug pipeline and strong growth potential. The firm ranks second among global pharma peers, with a 12-month price target of 14,200p, following a forecast-beating revenue surge of 21% for 2024. AstraZeneca's shares rose nearly 2% to 11,988.0p.
UBS has adjusted its ratings on key European pharmaceutical companies, downgrading Novartis to Neutral due to concerns over patent expirations and a limited pipeline, while upgrading Roche to Buy, citing strong growth prospects and a robust pipeline. AstraZeneca also received a Buy upgrade, driven by its sector-leading pipeline potential, with both companies seeing significant increases in their price targets.
UBS has downgraded Novartis to Neutral from Buy, citing concerns over patent expirations and a limited pipeline, with EBIT growth expected to decline significantly in 2025. In contrast, Roche and AstraZeneca received upgrades to Buy, driven by strong pipeline prospects and revenue growth potential, with Roche's price target raised to CHF 338 and AstraZeneca's to £142.
Nidwaldner Kantonalbank (NKB) reported a profit increase in 2024, with net operating income rising to CHF 45.8 million and a net profit of CHF 17.6 million, up 4.1%. The canton of Nidwalden will receive a dividend of CHF 10.4 million, reflecting a CHF 0.5 million increase from the previous year. Despite interest rate cuts, customer loans grew by 6.3%, driven by a strong mortgage sector, while the investment business saw a 15% rise in net commission income.
UBS has maintained a Neutral rating on EssilorLuxottica, keeping the target price at €266 after the 2024 results announcement. The company aims for annual sales growth of about 5% until 2026, projecting sales of €27-28 billion and adjusted operating income of 19-20% of sales, though achieving margin targets may be challenging.
JPMorgan Chase, Nomura, and UBS are set to face fines in South Korea for short-selling practices. UBS Group AG, a holding company, generates its revenues primarily from wealth management (50.9%), followed by investment banking (20.8%), retail and corporate banking (20.2%), and asset management (6.3%). As of the end of 2023, UBS reported USD 792 billion in current deposits and USD 639.8 billion in current loans.
Industry Trends
SubCategory
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche shares rise after UBS upgrades recommendation to buy
14:33 13.02.2025
siemens ag maintains strong market position with diverse product offerings
14:23 13.02.2025
Pfizer reports strong fourth quarter results and maintains positive 2025 outlook
14:10 13.02.2025
Celldex receives buy rating from UBS according to market report
13:55 13.02.2025
ubs upgrades astrazeneca to buy citing strong drug pipeline and growth potential
13:20 13.02.2025
ubs adjusts ratings on european pharma stocks novartis downgraded roche upgraded
13:14 13.02.2025
ubs downgrades novartis while upgrading roche and astrazeneca ratings
British Pound Sterling
Swiss Franc
AstraZeneca PLC
Novartis AG
Hoffmann-La Roche AG
GBR
CHE
Show more
13:01 13.02.2025
Nidwaldner Kantonalbank reports profit growth and increased dividend distribution
12:57 13.02.2025
ubs maintains neutral stance on essilorluxottica with steady growth outlook
12:57 13.02.2025
south korea fines jpmorgan chase nomura and ubs over short selling
12:29 13.02.2025
Trending
Subcategory
Stock Market Updates
Industry Trends
Corporate News
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Startups & Entrepreneurship
AI Innovations
Central Bank Actions
Government Policies
Funding Rounds & Investments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Banking Regulations
Supply Chain Management
Domestic Politics
AI & Automation Regulations
Global Trade Developments
Government Economic Policies
Emerging Startups
Countries:
Companies:
NVIDIA Corporation
Apple Inc.
Huawei Technologies CO. Ltd.
Tesla, Inc.
The Goldman Sachs Group, Inc.
Citigroup Inc.
Barclays PLC
Wells Fargo & Company
American Express Co
Bank of America Corporation
Tiktok USD
HSBC Holdings plc
Berkshire Hathaway Inc.
International Monetary Fund FUND
HDFC Bank Ltd
Coca-Cola FEMSA, S.A.B. de C.V.
Nintendo Co., Ltd.
Raiffeisen Bank International AG
Pfizer Inc.
VP Bank AG
Currencies:
United States Dollar
Euro
Japanese Yen
Indian Rupee
United Arab Emirates Dirham
Chinese Yuan
Swiss Franc
British Pound Sterling
Offshore Chinese Yuan
Saudi Riyal
Australian Dollar
Brazilian Real
South Korean Won
Hong Kong Dollar
Norwegian Krone
People: